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Metabolic reprogramming is a hallmark of clear cell
renal cell carcinoma (ccRCC) progression. Here, we
used genome-scale metabolic modeling to elucidate
metabolic reprogramming in 481 ccRCC samples
and discovered strongly coordinated regulation of
glycosaminoglycan (GAG) biosynthesis at the tran-
script and protein levels. Extracellular GAGs are
implicated in metastasis, so we speculated that
such regulation might translate into a non-invasive
biomarker for metastatic ccRCC (mccRCC). We
measured 18 GAG properties in 34mccRCC samples
versus 16 healthy plasma and/or urine samples. The
GAG profiles were distinctively altered in mccRCC.
We derived three GAG scores that distinguished
mccRCC patients with 93.1%–100% accuracy. We
validated the score accuracies in an independent
cohort (up to 18 mccRCC versus nine healthy) and
verified that the scores normalized in eight patients
with no evidence of disease. In conclusion, coordi-
nated regulation of GAG biosynthesis occurs in
ccRCC, and non-invasive GAG profiling is suitable
for mccRCC diagnosis.
INTRODUCTION
Clear cell renal cell carcinoma (ccRCC) is themost common form
of kidney cancer (Rini et al., 2009), and it is responsible for
100,000 deaths worldwide (Ferlay et al., 2010). Approximately
50% of patients with ccRCC are expected to develop metastatic
disease, which is usually incurable. In sharp contrast to early
diagnosed ccRCC, the median survival of patients with metas-1822 Cell Reports 15, 1822–1836, May 24, 2016 ª 2016 The Author(s
This is an open access article under the CC BY-NC-ND license (http://tasis is significantly worse (Gupta et al., 2008), even with
improved prognosis after the introduction of modern targeted
therapies (Wahlgren et al., 2013). This fact constitutes a major
and unmet clinical problem because, despite the need for both
early prediction and frequent monitoring of metastatic ccRCC,
no biomarkers are currently approved as part of the clinical man-
agement of the disease, resulting in late diagnosis or unknown
responses to treatment (Jonasch et al., 2012; Moch et al., 2014).
The search for molecular biomarkers has focused on ccRCC
genetics and angiogenesis, but none of these biomarkers has
entered routine clinical practice, nor are they easily accessible
or indicative of metastasis (Finley et al., 2011; Moch et al.,
2014). In contrast, other molecular processes prominent in
ccRCC might fill this gap. In this sense, accumulating evidence
has suggested that the proliferation and survival of cancer cells
rely upon a shift in their metabolism (Schulze and Harris, 2012;
Vander Heiden et al., 2009; Ward and Thompson, 2012). In
particular, ccRCC has recently been shown to feature strong
regulation and dependence on distinctive metabolic reprogram-
ming, which is pivotal to its progression (Creighton et al., 2013;
Gatto et al., 2014, 2015; Hakimi et al., 2016; Li et al., 2014). These
outstanding metabolic changes might be of clinical interest
because they have the potential to be used as ccRCC
biomarkers.
Under these premises, we followed up on our recent study,
which revealed a deviating regulation of metabolism in ccRCC
in contrast with seven common epithelial tumors (Gatto
et al., 2014). Moreover, we further computationally character-
ized metabolic regulation of ccRCC, leveraging a larger number
of samples using state-of-the-art genome-scale metabolic
modeling (Bordbar et al., 2014; Jerby and Ruppin, 2012; Mardi-
noglu et al., 2013; Mardinoglu and Nielsen, 2015). As a result,
we discovered previously unreported coordinated regulation
of glycosaminoglycan (GAG) biosynthesis, which is exacerbated
in metastasis. This discovery led us to speculate that this)
creativecommons.org/licenses/by-nc-nd/4.0/).
regulation might be detectable in metastatic ccRCC. Hence, we
designed an observational study to measure GAG profiles in the
accessible fluids of metastatic ccRCC patients and sought to
characterize the suitability of GAG profiles as diagnostic markers
for the disease.
RESULTS
Metabolic Modeling Reveals Differential Regulation of
GlycosaminoglycanBiosynthesis inClear Cell Renal Cell
Carcinoma versus Non-cancerous Kidneys
Our recent study suggested that metabolic reprogramming in
ccRCC is unique and likely occurs due to genetic alterations
in tumor progression (Gatto et al., 2014). The exceptional nature
of metabolic regulation in ccRCC could have important clinical
implications as a potential molecular biomarker. Thus, we
sought to characterize fully metabolic regulation in ccRCC
computationally. We retrieved a larger number of gene expres-
sion profiles from The Cancer Genome Atlas (TCGA) than in our
previous study (481 tumor samples versus 71 tumor-adjacent
normal samples, here simply referred to as ‘‘non-tumor,’’; Table
S1) and performed differential gene expression analysis (Law
et al., 2014). We integrated the gene expression changes asso-
ciated with ccRCC using genome-scale metabolic modeling to
pinpoint deregulation at the levels of metabolic pathways and
connected components in the metabolic network. In the first
case, we used piano (Va¨remo et al., 2013) to perform consensus
gene-set analysis of KEGG metabolic pathways and to deter-
mine the pathways that were significantly deregulated in ccRCC
and in which direction (i.e., up- or downregulated). In the second
case, we first calculated the metabolites that were mostly
affected by gene expression changes and then clustered these
metabolites in the human metabolic network using Kiwi (Va¨remo
et al., 2014) to emphasize whether specific pathway compo-
nents were regulated. At the pathway level, we observed wide-
spread downregulation of central carbon and amino acid meta-
bolism, steroid biosynthesis, heparan sulfate biosynthesis, and
other catabolic processes (Figure 1A). Biosynthesis of chon-
droitin sulfate was the only significantly upregulated pathway
when both considering only upregulated genes (mixed direc-
tionality) and considering all genes weighted by their statistical
significance (distinct directionality). Consistently, at the metab-
olite level, we observed downregulation of genes associated
with metabolites related to branched-chain amino acids (e.g.,
3-hydroxyisobutyrate) and steroids (e.g., 3-hydroxy-3-methyl-
glutaryl-coenzyme A, also known as HMG-CoA) (Figure S1).
Interestingly, whereas most metabolites interact through central
carbon metabolites, this analysis returned an unconnected
sub-network of metabolites that comprised precursors of chon-
droitin and heparan sulfate, with opposite directions of regula-
tion (Figure 1B). The repression of central carbon and amino
acid metabolism was in agreement with previous computational
analyses (Creighton et al., 2013; Gatto et al., 2014), which were
recently experimentally validated (Cuperlovic-Culf et al., 2016;
Nilsson et al., 2015). However, both analyses revealed distinct
and opposite regulation of chondroitin and heparan biosyn-
thesis, which closely interacts within the glycosaminoglycan
biosynthesis pathway. Given that this finding was not previouslyreported, we sought to explore glycosaminoglycan biosynthesis
in further detail.
Glycosaminoglycan Biosynthesis Displays Coordinated
Regulation Specific to Clear Cell Renal Cell Carcinoma
at the Transcript and Protein Levels
Chondroitin (CS) and heparan (HS) sulfates are glycosamino-
glycans (GAGs) that share a common biosynthetic route in the
linkage to the core protein, but thereafter, they differ in polymer-
ization: CS, repeating disaccharides, is constituted by N-acetyl-
galactosamine and glucuronic acid residues, while HS, repeating
disaccharides, is constituted by N-acetylglucosamine and glu-
curonic acid residues (Kreuger and Kjelle´n, 2012; Mikami and Ki-
tagawa, 2013). In ccRCC, we observed coordinated regulation of
GAG biosynthesis, defined by substantial upregulation of most
genes specific to CS biosynthesis (11/13) and concurrent down-
regulation of genes specific to HS biosynthesis (8/13), indicating
a potential change in GAG disaccharide composition, sulfation,
and chain length in ccRCC (Figure 2A; Table S2). We confirmed
this coordinated regulation of GAG biosynthesis in two indepen-
dent datasets that compared gene expression in ccRCC versus
non-tumor samples (Pen˜a-Llopis et al., 2012; Wang et al., 2009),
with strong and significant correlations between expression fold
changes in these studies and the TCGA samples (Pearson’s cor-
relation coefficient r = 0.87–0.89; Figure 2B).
To verify the extent to which this regulatory pattern is ccRCC
specific, we repeated an analogous analysis of six other epithe-
lial cancer types for which at least 20 tumor-adjacent normal
samples were found in TCGA (i.e., breast invasive carcinoma,
colon adenocarcinoma, head and neck squamous cell carci-
noma, lung adenocarcinoma, lung squamous cell carcinoma,
and uterine corpus endometrial carcinoma). None of these can-
cers displayed the same coordinated pattern as in ccRCC, which
was a clear outlier according to unsupervised hierarchical clus-
tering, although we found cancer-type-dependent regulation of
individual enzymes involved in GAG biosynthesis (Figure 2C; Ta-
ble S2). In addition, we never observed both the CS and the HS
biosynthesis pathways among the top ranked regulated path-
ways in any of these cancer types (Figure S2).
To evaluate whether the coordinated regulation of GAG biosyn-
thesis is also represented at the level of protein expression, we
used immunohistochemistry on a ccRCC tissue microarray to
detect thepresenceof three representativeproteins characteristic
of the pathway (CHPF2 in CS biosynthesis and HS6ST2 and
EXTL1 in HS biosynthesis) in ccRCC versus normal kidney sam-
ples (Figure 2D). In accordance with gene expression changes,
CHPF2displayed strongstaining in all of the tested tumor samples
(positive in 21 of 21 samples) and only weak and likely unspecific
staining in the kidney proximal tubule cells (0/2); HS6ST2 showed
weak or no staining in all of the tested tumor samples (positive in
zero of 32), while it was detected in both the podocytes in the
kidney glomeruli and the endothelial cells of larger vessels (2/2);
and EXTL1 was undetected in 96% of the tested tumor samples
(positive in one of 27), but it was stained strongly in the kidney-col-
lectingductcells (twoof two) (representativesamples inFigure2E).
Taken together, these results suggested that coordinated regula-
tion ofGAGbiosynthesis is a prominentmetabolic event occurring
exquisitely in the kidney during ccRCC transformation.Cell Reports 15, 1822–1836, May 24, 2016 1823
BD
is
tin
ct
−
di
re
ct
io
na
l (d
n)
M
ixe
d −
di
re
ct
io
na
l (d
n)
N
on
−
di
re
ct
io
na
l
M
ixe
d −
di
re
ct
io
na
l (u
p)
D
is
tin
ct
−d
ire
ct
io
na
l (u
p)
OXIDATIVE PHOSPHORYLATION
GLYCINE SERINE AND THREONINE METABOLISM
ARGININE AND PROLINE METABOLISM
PYRUVATE METABOLISM
FATTY ACID METABOLISM
BUTANOATE METABOLISM
CITRATE CYCLE TCA CYCLE
VALINE LEUCINE AND ISOLEUCINE DEGRADATION
PROPANOATE METABOLISM
GLYCOLYSIS GLUCONEOGENESIS
TRYPTOPHAN METABOLISM
TYROSINE METABOLISM
SELENOAMINO ACID METABOLISM
BETA ALANINE METABOLISM
NITROGEN METABOLISM
CYSTEINE AND METHIONINE METABOLISM
GLYOXYLATE AND DICARBOXYLATE METABOLISM
STEROID BIOSYNTHESIS
LYSINE DEGRADATION
TERPENOID BACKBONE BIOSYNTHESIS
LIMONENE AND PINENE DEGRADATION
ARACHIDONIC ACID METABOLISM
GLYCOSAMINOGLYCAN BIOSYNTHESIS HEPARAN SULFATE
NICOTINATE AND NICOTINAMIDE METABOLISM
GLYCOSAMINOGLYCAN BIOSYNTHESIS CHONDROITIN SULFATE
−4 −2 0 2 4
0 2 4
-log10 consensus gene-set p
Directional log10 consensus gene-set p
A
heparan sulfate, precursor 13[g]
heparan sulfate, precursor 15[g]
G00021[g]
chondroitin sulfate A
(GalNAc4S-GlcA), B
(IdoA2S-GalNAc4S), and E
(GalNAc4,6diS-GlcA), precursor
1[g]
chondroitin sulfate C
(GalNAc6S-GlcA) and D
(GlcNAc6S-GlcA2S), precursor
1[g]
(alpha-D-mannosyl)5-beta-D-mannosyl-diacetylchitobiosyl-L-asparagine
(protein) (B1)[g]
(alpha-D-mannosyl)4-beta-D-mannosyl-diacetylchitobiosyl-L-asparagine
(protein)[g]
chondroitin sulfate B
(IdoA2S-GalNAc4S), precursor
4[g]
chondroitin sulfate D
(GlcNAc6S-GlcA2S)
precursor 2[g]
heparan sulfate, precursor 12[g]
chondroitin sulfate A
(GalNAc4S-GlcA) proteoglycan[g]
Metabolite-neighbouring genes
Up-regulationDown-regulation
Figure 1. Integrated Metabolic Modeling
and Differential Gene Expression Analysis
in ccRCC versus Tumor-Adjacent Normal
Kidney Tissue
(A) Consensus gene-set analyses for KEGG meta-
bolic pathways in ccRCC versus tumor adjacent
normal samples. Each entry shows the median
gene-set p value for a pathway among six different
gene-set analysis methods. Every column repre-
sents a different regulatory direction: Dist(dn),
distinct directional down;Mix(dn),mixed directional
down; Nondir, non-directional; Mix(up), mixed
directional up; Dist(up), distinct directional up.
(B) An extract from an unbiased analysis of the
metabolic network aimed at detecting connected
metabolites, in which the neighboring genes were
prevalently up- (red) or downregulated (blue) (see
also Figure S1 for the complete network results).
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Figure 2. Coordinated Regulation of Glycosaminoglycan Biosynthesis in ccRCC versus Tumor-Adjacent Normal Kidney Tissue at the
Transcript and Protein Levels
(A) Pathway view of glycosaminoglycan biosynthesis in ccRCC. Each box shows the enzyme(s) carrying out a given reaction in the pathway. The color represents
the log10 fold change in ccRCC versus non-tumor tissue for the enzyme-coding gene, while the symbol next to each box indicates the significance of the
corresponding gene regulation (in terms of false discovery rate). The pathway is drawn according to KEGGgene associations (note that genes related to dermatan
sulfate biosynthesis or sulfation at C3 in heparan sulfate are not shown, the latter event being rarely observed [Thacker et al., 2014]). Solid arrows indicate the
addition of a molecule, dashed lines indicate the conversion of a molecule, and dotted lines indicate the final disaccharide composition up to that point.
(B) Correlation of gene expression log2 fold changes in the glycosaminoglycan biosynthesis pathway between TCGA samples (y axis) and two independent
studies (GSE36986 and GSE14762 [Pen˜a-Llopis et al., 2012; Wang et al., 2009]).
(C) Gene expression log2 fold changes in the glycosaminoglycan biosynthesis pathway in ccRCC, compared to other cancers versus matched non-tumor tissue.
HNSC, head and neck squamous cell carcinoma; BRCA, breast invasive carcinoma; COAD, colon adenocarcinoma; LUAD, lung adenocarcinoma; LUSC, lung
squamous cell carcinoma; UCEC, uterine corpus endometrial carcinoma. See also Figure S3 for gene expression analysis in other cancers at the pathway level.
(D) Fraction of the samples positive for immunohistochemical staining of CHPF2, HS6ST2, and EXTL1 in ccRCC (21–27 tissue samples) versus normal kidney (two
samples). The results are presented as the consensus of staining performed in duplicate.
(E) Immunohistochemical staining for CHPF2, HS6ST2, and EXTL1 in representative ccRCC and normal samples.Altered Regulation of Glycosaminoglycan Biosynthesis
Is Exacerbated in Metastasis and Is Detectable in
Patients’ Urine and Plasma
CS and HS have been long implicated in the regulation of angio-
genesis, adhesion, invasion, and migration, which are key stepsin the metastatic cascade (Afratis et al., 2012; Jackson et al.,
1991). We extended our differential gene expression analysis to
verify whether the genes involved in GAG biosynthesis showed
further regulation in ccRCC patients with metastasis. We found
that 11 genes involved in GAG biosynthesis were differentiallyCell Reports 15, 1822–1836, May 24, 2016 1825
Table 1. Clinical Data for the Discovery and Validation Cohorts
mccRCC (n = 34) Healthy (n = 16) mccRCC (n = 18) Healthy (n = 9)
Cohort Characteristics
Class Discovery Discovery Validation Validation
Both plasma and urine samples 13 16 7 9
Only plasma samples 21 0 11 0
Baseline Characteristics
Age (range, years) 64.6 (59.2–70.5) 62.7 (57.6–65) 56.1 (50.7–64.6) 55.2 (42.2–64.3)
Female 23.1% 62.5% 14.3% 44.4%
Caucasian 100% 100% 100% 100%
BMI (kg/m2) 26.1 (23.7–26.7) 25.7 (22.8–29.1) 23.1 (22.3–28.8) 23.5 (21.7–25.8)
Current Oncological Therapy
None 64.7% 100% 61.1% 100%
Sunitinib 20.6% 0% 27.8% 0%
Other antineoplastic agents 14.7% 0% 11.1% 0%
Lifestyle Characteristics
Physical exercise (hr/week) 2 (2–3.5) 3 (2–6) 3 (3–4.75) 4 (3–7)
Bread consumption (servings/week) 10 (7–14) 10 (6.25–14.5) 14 (12–14) 7 (4–7)
Pizza consumption (servings/week) 1 (0.5–1) 0 (0–0) 1 (0.25–1) 0 (0–1)
Pasta consumption (servings/week) 7 (5–7) 1 (0.5–1) 7 (5–7) 2 (0–3)
Rice consumption (servings/week) 3 (2–3) 1 (1–2) 2 (1.5–3) 1 (1–1)
Alcohol consumers 23.1% 87.5% 71.4% 100%
Fiber consumers 23.1% 50% 57.1% 66.7%
Smoking Habits
Never smokers 61.5% 56.25% 71.4% 66.7%
Ex smokers 38.5% 37.5% 28.6% 33.3%
Smokers 0% 6.25% 0% 0%
All results are presented asmedians (25th, 75th percentile) or percentages. Missing values were omitted. Detailed clinical data are reported in Table S3.regulated in metastasis, exacerbating the overexpression of CS-
associated genes and the suppression of HS-associated genes
(Figure S3). This finding suggested that coordinated regulation
ofGAGbiosynthesis isanevent exacerbatedbymetastasis.While
the assembly of GAG chains occurs intracellularly, the completed
proteoglycan is secreted in the extracellular matrix (Silbert and
Sugumaran, 2002). Hence, considered together, we speculated
that not only might eventual changes in GAGs due to ccRCC
progression be reflected in kidney-proximal fluids, but also
these changes should be easier to detect in metastatic ccRCC
(mccRCC) patients. This speculation leverages on variations in
GAG concentration and composition having been observed in
the proximal fluids of other diseases in which GAGs were impli-
cated (Anower-E-Khuda et al., 2013; Mannello et al., 2014,
2015; Schmidt et al., 2014; Schmidt et al., 2016; Volpi et al., 2015).
To verify whether changes in theGAGprofile occur inmccRCC
and could be measured in accessible body fluids, we recruited a
discovery cohort of 50 subjects, consisting of 34 patients with
mccRCC and 16 healthy individuals (Table 1; Table S3). Plasma
and urine samples were obtained from all of the subjects, except
for 21 mccRCC patients from whom only plasma samples were
available. CS and HS concentrations and their disaccharide
compositions were quantified in the samples using liquid chro-
matography with online electrospray ionization mass spectrom-
etry (ESI-MS). In total, 18 independent GAG properties were1826 Cell Reports 15, 1822–1836, May 24, 2016measured in every fluid sample (note that the GAG charge is
the sum of all of the sulfated disaccharide fractions). The collec-
tion of all of these data points defined a GAG profile. We
observed remarkable differences between the GAG profiles of
mccRCC patients and those of healthy individuals, both in the
plasma and urine samples (Figure 3A). Principal component
analysis (PCA) of GAG profiles that combined plasma and urine
measurements revealed that mccRCC patients were clearly
separate from healthy individuals (71% of the variance was ex-
plained by the first component; Figure 3B). Similar separations
were achieved using only plasma measurements (81% variance)
or urine measurements (63% variance). These results indicated
that mccRCC entails alterations in systemic GAG composition
that are markedly distinct from those of healthy individuals.
Design of mccRCC Biomarkers Based on Plasma and
Urine GAG Profiles
The changes in the plasma and urine GAG profiles, which were
largely attributable to the occurrence of mccRCC, opened the
opportunity to design accessible biomarkers based on the GAG
properties that best distinguished the disease from a healthy
state. We utilized Lasso penalized logistic regression (Tibshirani,
1996) with leave-one-out cross-validation to select robust GAG
properties that are most predictive of clinical outcomes (i.e.,
mccRCC versus healthy). A biomarker score was subsequently
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designed as a ratio, where the numerator is the sum of the prop-
erties associated with mccRCC, and the denominator is the sum
of theproperties associatedwith thehealthy state. Each termwas
normalized using the regression coefficients. We derived three
potential disease biomarker scores, based on either plasma or
urine or on combined measurements:
Plasma score=
½6s CS+CStot
3
10
½4s CS
½6s CS+ ½Ns HS
Urine score=
½Ns6s HS+ 60,Charge HS
½4s CS
Combined score=meanðPlasma score;Urine scoreÞ
where terms in brackets represent the fraction of the disaccha-
ride for the corresponding GAG (the abbreviations describe
different sulfation patterns for CS and HS as per Figure 1B),
CStot is the total concentration of CS (in mg/mL), and
Charge HS is the total fraction of sulfated disaccharides of HS.
We then calculated the three scores for each sample and
observed that the mccRCC samples had recurrently elevated
scores, compared to healthy samples (Figure 4A). We computed
significant non-null mean differences in all three scores between
the two groups using robust Bayesian estimation. The mean dif-
ference was equal to 2.15 for the combined score (95% high-
density interval [HDI] 1.72–2.60), 2.49 for the plasma score
(95% HDI 1.94–3.05), and 0.79 for the urine score (95% HDI
0.52–1.06). The performance of the three biomarkers was evalu-
ated using receiver operating characteristic (ROC) curves, and
the area under the curve (AUC) was found to be 1 (perfect clas-
sifier) in the case of the combined and plasma scores and 0.966
for the urine score (Figure 4B; Table 2). A straightforward clinical
implementation of these biomarkers would be to predict occur-
rence of the disease, for example, to monitor mccRCC patients
after surgery or to diagnose response to treatment using a simple
non-invasive test, in addition to or as a substitute for standard
radiological tests. Thus, from each ROC curve, we computed a
score cutoff that maximized the positive predictive value (PPV)
of the biomarker (Lopez-Raton et al., 2014) (Table 2). Taken
together, these findings demonstrated that alterations in plasma
and urine GAG composition occurring inmccRCC could be sum-
marized as scores. In turn, these scores accurately distinguished
patients with from healthy individuals, emphasizing their poten-
tial as disease biomarkers.Validation of themccRCCBiomarkers in an Independent
Cohort and in Patients with No Evidence of Disease
To validate whether these scores had reproducible accuracy in
an independent cohort, we recruited 27 subjects, consisting ofFigure 3. The Glycosaminoglycan Plasma and Urine Profiles of mccRC
(A) The glycosaminoglycan profiles of mccRCC patients (gray boxplots) versus h
urine (bottom, 13 versus 16 samples). Each profile consists of 18 independent me
the total concentration and the disaccharide composition.
(B) Principal component analysis of sample GAG profiles, using measurements f
1828 Cell Reports 15, 1822–1836, May 24, 201618 patients with mccRCC and nine healthy individuals (Table 1;
Table S3). Plasma and urine samples were obtained from all of
the subjects, except for 11 mccRCC patients from whom only
plasma samples were available. We analyzed the three bio-
markers for each individual and computed the corresponding
scores. The scores were also remarkably higher in mccRCC
patients compared with healthy controls in this validation cohort
(Figure 4C). We computed an AUC value equal to 1 for all
three biomarkers (Figure 4D). Additionally, the specificity at the
previously determined cutoff score was 100% for all of the
biomarkers, consistent with their potential to predict positive di-
agnoses (Table 2). This evidence strongly suggested that the
three biomarkers could indicate the occurrence of mccRCC by
means of a non-invasive analytical test.
We sought to verify whether the scores would normalize in
subjects previously diagnosed with mccRCC but with no evi-
dence of disease, which would strongly suggest that the bio-
markers follow mccRCC and are suitable for monitoring its
progression. In addition, we could not exclude that previous
exposure to the disease might have prolonged effects on sys-
temic GAG composition. Therefore, we analyzed GAGs in the
plasma and urine of a prospective cohort of eight individuals
diagnosed with mccRCC but with no evidence of disease at
the time of sampling. The GAG profiles in the urine and the
plasma were remarkably distinct from those of patients with
mccRCC and shifted toward the profiles of healthy individuals
(Figure 5A). When we computed the biomarker scores using
the same formulas designed above, we observed a significant
decrease compared to the expected value in mccRCC (mean
difference in the combined score, 0.94, 95% HDI 0.72–1.17; in
the plasma score, 0.86, 95% HDI 0.69–1.03; in the urine score,
0.72, 95% HDI 0.40–1.07). The accuracy of the test based on
the previously identified cutoffs was high for both the plasma
and urine scores, with seven of eight cases less than the cutoff
and hence 87.5% of the subjects were correctly identified as
not having mccRCC (Figure 5B). The accuracy was lower for
the combined score, with six of eight subjects (75%) correctly
classified according to the cutoff. Although only a longitudinal
study could corroborate a positive correlation between the tu-
mor burden and these scores, these results argued that plasma
and urine GAG composition could be used as a robust and accu-
rate diagnostic biomarker for the occurrence of mccRCC.
Analysis of the Predictive Value of mccRCC Biomarkers,
Accounting for Confounding Factors
We sought to identify the extent to which the measured systemic
GAG alterations were purely attributable to ccRCC progression,
as suggested by the underlying transcriptional regulation, or
whether they were also dependent on other confounding factors.
Therefore, we gathered clinical and dietary information that
could confound the associations of the scores with clinical out-
comes for 33 individuals (17 mccRCC patients and 16 healthyC Patients Are Markedly Distinct from Those of Healthy Individuals
ealthy individuals (orange boxplots) in plasma (top, 34 versus 16 samples) and
asurements of GAGs (nine related to CS and nine related to HS), which refer to
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Figure 4. The Glycosaminoglycan Profile Can Be Summarized in Three Scores Based on Measurements in the Plasma, Urine, or Both that
Can Accurately Predict the Occurrence of mccRCC
(A) Plasma, urine, and combined scores in mccRCC patients (gray boxplots) versus healthy individuals (orange boxplots) belonging to the discovery cohort
(34 versus 16 plasma samples and 13 versus 16 urine samples).
(B) Receiver operating characteristic (ROC) curves in the classification of samples of the discovery cohort as either mccRCC or healthy, based on the combined,
plasma, and urine scores. For each biomarker, an optimal cutoff scores that maximized the positive predictive value is indicated.
(legend continued on next page)
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Table 2. Measures of Accuracy for GAG Scores in the Prediction of mccRCC for the Discovery and Validation Cohorts at the Optimal
Cutoff Score
AUC Optimal Cutoff Score Accuracy Specificity Sensitivity
Discovery Cohort
Combined marker 1 0.616 100% 100% 100%
Plasma marker 1 0.234 100% 100% 100%
Urine marker 0.966 1.133 93.1% 100% 84.6%
Validation Cohort
Combined marker 1 — 100% 100% 100%
Plasma marker 1 — 92.6% 100% 77.8%
Urine marker 1 — 93.7% 100% 85.7%
The optimal cutoff score was calculated in the discovery cohort and verified in the validation cohort.patients; Table S3). As reported in Table 1, we observed an un-
even distribution of some baseline characteristics, for example,
gender, pasta consumption, and alcohol consumption. There-
fore, we tested whether the clinical outcomes could be purely
inferred by some of the confounding factors, rather than by the
biomarker scores. First, we determined the most biased factors
between the mccRCC versus healthy groups. To this end, we re-
gressed the clinical outcome based on the confounding factors
and the combined score using Lasso penalized logistic regres-
sion. This analysis selected four potentially relevant confounding
factors: age; weekly consumption of pasta and rice; and use of
alcohol. Then, we performed analysis of covariance using logis-
tic regression to test the strength of the association between
clinical outcome and the combined score, using the four con-
founding factors as covariates. Notably, none of the covariates
made a significant contribution to the regression of the clinical
outcome (p = 0.27 and 0.44; Figure S4). In addition, we calcu-
lated that the logistic regression model based solely on the com-
bined score was the most likely model (p = 99.2%), according to
the minimum Kullback-Leibler divergence criterion: the Akaike
information criterion for the regression based on the combined
score only was significantly lower than for the regression based
also on the four covariates (7.8 versus 17.5, respectively). A
similar conclusion was reached for the plasma score (6.0 versus
17.9) but not for the urine score (23.0 versus 17.5), for which
pasta consumption displayed a significant effect in the regres-
sion of the clinical outcome (p = 0.03). Taken together, these
results indicated that the combined and plasma scores alone
(but not the urine score) had strong associations with the clinical
outcome regardless of any here-considered confounding fac-
tors, prompting the use of GAGmeasurements as unbiased pre-
dictors of the occurrence of mccRCC.
Finally, we explored whether systemic therapy had an effect
on the biomarker scores, given that these scores were calcu-
lated by profiling body fluids. We limited our analysis to the pa-
tients for whom only plasma samples were collected (and hence,
we checked solely the effect on the plasma scores) because, for(C) Plasma, urine, and combined scores in mccRCC patients (gray boxplots) vers
versus nine plasma samples and seven versus nine urine samples).
(D) ROC curves in the classification of samples of the validation cohort as either m
Figure S5 for score correlations with confounding factors.
1830 Cell Reports 15, 1822–1836, May 24, 2016this group, we noted a comparable number of treated (n = 19)
and untreated (n = 33) patients. We did not observe any signifi-
cant correlation between the plasma score and the use of sys-
temic therapy, based on a linear regression of the score on the
treatment status of the sample (p = 0.518) and the type of treat-
ment (sunitinib versus other regimens, p = 0.508). Overall, these
analyses of covariance showed that GAG measurements, in the
form of the proposed scores, could robustly predict the occur-
rence of mccRCC despite baseline and treatment differences
across patients. This robustness was likely due to coordinated
regulation of GAG biosynthesis intrinsic to ccRCC progression,
mirrored at the level of kidney-adjacent fluids.
DISCUSSION
This study revealed that coordinated regulation of GAG biosyn-
thesis, which features concurrent upregulation of the branch
leading to CS formation and downregulation of the branch lead-
ing to HS formation, is a prominent event in ccRCC. Additionally,
many pathway-associated genes are further up- or downregu-
lated in metastasis. This discovery can be attributed to an
increased number of samples and recent advances in metabolic
network analysis: indeed, traditional gene-set enrichment anal-
ysis likely misses the distinctive regulation of the two branches
within the gene set because the opposite fold changes would
cancel each other out. However, even considering the large
sample size and the independent validation with tissue micro-
arrays, we cannot completely exclude that other systematic
confounding factors might partially explain the observed differ-
ential regulation, most importantly local inflammation in the kid-
ney, which can occur concomitantly with other renal diseases
unrelated to cancer. At the same time, altered expression of
CS and HS, particularly in glycan composition and sulfation,
has been indicated in the promotion of migration, metastasis,
and angiogenesis in a number of tumor models, including
skin (Smetsers et al., 2004), lung (Mizumoto et al., 2012),
brain (Wade et al., 2013), and breast (Ferna´ndez-Vega et al.,us healthy individuals (orange boxplots) belonging to the validation cohort (18
ccRCC or healthy, based on the combined, plasma, and urine scores. See also
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Figure 5. The Glycosaminoglycan Profile and Combined, Plasma, and Urine Scores in Subjects Previously Diagnosed with mccRCC but with
No Evidence of Disease at the Time of Sampling
(A) Principal component analysis of GAG profiles using measurements from both plasma and urine in healthy subjects, mccRCC patients, and subjects with no
evidence of disease (NED, eight samples).
(B) Biomarker scores in NED and all mccRCC subjects analyzed in this study. The horizontal lines represent the optimal cutoff scores at which a subject was
classified as either with mccRCC or as healthy.
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2013); however, contrary to these studies that focused on indi-
vidual GAG types, our work reports an extensive, consistent,
and coordinated regulation of the whole biological process of
GAG biosynthesis in a cancer type. The relevance of such pre-
cise regulation of GAGs in ccRCC could be attributed to the roles
of GAGs in the remodeling of the extracellular matrix, which
strongly depends on their composition and abundance (Afratis
et al., 2012). For example, a chondroitin sulfate-rich matrix was
linked to the development of self-contained and defined lesions
in lower grade glioma (compared to the microscopic infiltrations
typical of glioblastomas) (Silver et al., 2013), which is a tumor
growth model closely resembling ccRCC (Rini et al., 2009). How-
ever, it remains to be explored how this regulatory program is
mechanistically linked to metastasis, rather than representing a
coordinated metabolic event attributable to the remodeling of
the kidney caused by the disease.
Because GAGs localize and act in the extracellular matrix, we
assumed that changes in their regulation would reflect changes
in their profiles in body fluids proximal to the kidney, e.g., blood
and urine, as observed in other pathologies (Anower-E-Khuda
et al., 2013; Mannello et al., 2014, 2015; Schmidt et al., 2014,
2016; Volpi et al., 2015). In particular, this behavior should be
exacerbated in metastasis. Currently, there is no diagnostic
biomarker that has entered routine practice for metastatic
ccRCC (Jonasch et al., 2012; Moch et al., 2014). At the same
time, metastatic disease is invariably incurable, although rare
complete responses have been reported in association with
oncological targeted therapies with or without metastasectomy
(Albiges et al., 2012). Therefore, it would undoubtedly represent
an important clinical advancement if changes in the GAG profile
could constitute an indicator of the occurrence of the disease.
The availability of such a test would be valuable for a number
of medical decisions: to monitor ccRCC before and after surgery
or systemic treatment; to exclude relapse of the disease also
over longer periods of time, after which a patient is typically
declared cured; to assess the occurrence of ccRCC in a popula-
tion at risk, such as genetically predisposed individuals; to
ascertain whether metastasis is due to ccRCC or other neo-
plasms; and to follow treatment response in mccRCC. Our vali-
dation findings provided proof of concept that the here-designed
biomarker scores might effectively aid in undertaking some of
these clinical decisions because they are calculated based on
non-invasive measurements that are predictive of the clinical
outcome and are independent of the here-considered confound-
ing factors; most importantly, they are accurate and robust pre-
dictors of the disease.
The plasma and urine GAG profiles loosely resembled the ex-
pected patterns from the underlying transcriptional regulation,
i.e., increased concentration and sulfation of CS relative to HS
in ccRCC. Notably, a recent characterization of the GAG profile
in early-stage ccRCC tissues was strongly correlated with the
here-uncovered regulatory program (Ucakturk et al., 2016). In
addition, a previous study examined CS/HS concentrations in
early-stage ccRCC tissue samples (Batista et al., 2012), and
re-elaboration of these data to emphasize the CS/HS ratio delin-
eated a consistent trend (Figure S5). Overall, these data and our
study were suggestive of an active and early role for ccRCC in de
novo GAG production, likely stemming from gene expression1832 Cell Reports 15, 1822–1836, May 24, 2016regulation. At the same time, the GAG profiles revealed some
novel biological insights attributable to the occurrence of this
cancer type. The GAG composition in the plasma of healthy indi-
viduals is typically not affected by any tissue. Here, we observed
systemic alteration of GAG composition concomitant with meta-
static ccRCC. The enrichment of chondroitin-4-sulfate and
chondroitin-6-sulfate and 6-O-sulfated HS in mccRCC samples
was strikingly reminiscent of the GAG composition of lympho-
cytes (Shao et al., 2013). It is therefore tempting to speculate
that infiltration of the immune system in mccRCC could underlie
the observed transcriptional regulation in the tumor. In the urine,
the GAG composition in healthy individuals has not been as well
characterized. The alterations reported here in the GAG profiles
ofmccRCC samplesmight reflect progressive damage to cells in
the kidney glomeruli (McCarthy and Wassenhove-McCarthy,
2012; Miner et al., 2011). Collectively, this evidence seemed to
emphasize the importance of alterations in GAGs in the progres-
sion of ccRCC. Intriguingly, the uniqueness of these GAG alter-
ations could be exploited to deliver drugs specifically to ccRCC,
as recently shown by a study in which cancer was targeted using
a GAG-binding malaria protein (Salanti et al., 2015).
Thus far, among the major difficulties that have impaired
biomarker discovery and its translation into clinical practice
have been the detection of targets in accessible samples and
the reproducibility of results (Sawyers, 2008). Here, we provided
evidence for a plasmatic and/or urinary biomarker of metastatic
ccRCC that was supported by an intensely and consistently
regulated biological process in ccRCC samples. We envision
that future longitudinal studies that monitor the trend between
the tumor load and scores might establish these biomarkers
for a diverse range of diagnostic tools in the clinical management
of ccRCC.
EXPERIMENTAL PROCEDURES
Gene Expression Analysis
RNA sequencing (RNA-seq) gene expression profiles for 481 ccRCC primary
tumor and 71 tumor-adjacent normal-like samples were retrieved at The
Cancer Genome Atlas (TCGA) (Table S1). Differential expression analysis for
ccRCC versus non-tumor was performed using voom (Law et al., 2014).
2,090 genes with no annotation (3%) or no more than ten counts in less than
10% of the samples (7%) were discarded. The effect of metastasis was
accounted by adding the metastatic status of each sample as a covariate in
the linear model used in voom. Two independent microarray-generated data-
sets where retrieved in GEO (GEO: GSE36895 [Pen˜a-Llopis et al., 2012] and
GEO: GSE14762 [Wang et al., 2009]), and the differential expression analysis
for ccRCC versus non-tumor was performed using limma (Smyth, 2004). The
significance for changes in gene expression using either RNA-seq or microar-
ray data was tested using empirical Bayes estimation on a linear model for a
given comparison (in the case of RNA-seq the count variance was moderated
as proposed in voom [Law et al., 2014]). Consensus gene-set enrichment anal-
ysis (GSA) using piano (Va¨remo et al., 2013) was performed using as gene sets
either KEGG metabolic pathways or metabolites (i.e., a gene set is the list of
reaction-encoding genes that involve a given metabolite [Patil and Nielsen,
2005]), where the gene-set p value is defined as the median p value among
the following GSA methods: Fisher’s test, Stouffer’s test, reporter test, tail-
strength test, mean, and median. The significance of a gene set for each
GSA method was tested using a permutation test by shuffling gene labels
10,000 times. The gene sets ranked among the top 30 by most GSA methods
are shown in a heatmap that is hierarchically clustered. The differential gene
expression analysis andmultiple gene-set analysis (limited to KEGGmetabolic
pathways) was then repeated for six other cancer types (breast invasive
carcinoma, colon adenocarcinoma, head and neck squamous cell carcinoma,
lung adenocarcinoma, lung squamous cell carcinoma, and uterine corpus
endometrial carcinoma) compared to matched tumor-adjacent normal sam-
ples (which were also retrieved at TCGA; Table S1). All analyzed cancer types
were subsequently hierarchically clustered upon log2 fold change in the
expression of genes belonging to the KEGG glycosaminoglycan biosynthesis
pathways (excluding genes belonging to dermatan sulfate biosynthesis and
sulfotransferases on the C3 of heparan sulfate) compared to matched non-tu-
mor samples. Gene-set relatedness between gene sets was computed in
terms of the underlying network using Kiwi (Va¨remo et al., 2014), where
gene sets were considered related if the mutual shortest path length is lesser
than 2 in the network (to increase interpretability, gene sets with more than ten
genes were neglected). In the case of metabolites, the gene-set network was
extracted from the genome-scale metabolic model HMR2 (Agren et al., 2014).
The methods outlined above were implemented using the respective R-pack-
ages, except Kiwi that is a Python module.
Immunohistochemical Staining
A tissue microarray containing 32 ccRCC samples and two normal kidney
samples in duplicates was prepared and used for immunohistochemistry. An
experienced urological pathologist selected all cases. The ethical approval
was granted by the ethical committee at Lund University (LU289-07). Tissue
sections of 4 mm were deparaffinized and rehydrated according to standard
protocols. Antigen retrieval was performed using pressure cooking of the
samples for 20 min in 10 mmol/l citrate buffer (pH 6.0). Immunohistochemical
staining was performed using a Dako Techmate 500 unit, according to the
manufacturer’s instructions (Dako). Antibodies and dilutions used were
HPA020992 (CHPF2 1:35), HPA034625 (HS6ST2 1:125), and HPA037749
(EXTL1 1:35), all from Atlas Antibodies AB. Only tumor samples where both
duplicates could be scored were included in the analysis (21 for CHP2, 32
for HS6ST2, and 27 for EXTL1).
Sample Collection
In the discovery cohort, plasma and urine samples were obtained from 34
patients with metastatic clear cell renal carcinoma in two sites, IOV-IRCCS,
Padova, Italy and Sahlgrenska University Hospital, Go¨teborg, Sweden. For
21 patients, only plasma samples were obtained. A control group was formed
using 16 healthy individuals without any renal or liver malignancy, nor inflam-
matory pathologies. In the validation cohort, plasma and urine samples were
obtained from 18 patients with metastatic clear cell renal carcinoma in two
sites, IOV-IRCCS, Padova, Italy and Sahlgrenska University Hospital, Go¨te-
borg, Sweden. For 11 patients, only plasma samples were obtained. A control
group was formed using nine healthy individuals without any renal or liver ma-
lignancy, nor inflammatory pathologies. Samples from IOV-IRCCS, Padova,
Italy were collected from a consecutive series of patients scheduled for
mccRCC follow-up, prospectively. Samples from Sahlgrenska University Hos-
pital, Go¨teborg, Swedenwere retrieved from the bio-bank in the Department of
Urology and Oncology, retrospectively. All subjects provided written informed
consent. The present observational studywas notified to the Ethics Committee
at IOV-IRCCS, Padova, Italy in January 2013. The approval to collect and
analyze blood samples at the Sahlgrenska University Hospital, Go¨teborg,
Sweden was obtained from the Regional Ethics Board of Va¨stra Go¨taland,
Sweden. Whole-blood samples were collected in EDTA-coated tubes. The
tubes were centrifuged (2,500 3 g for 15 min at 4C), and the plasma was ex-
tracted and collected in a separate tube. Urine were collected in polypropilene
tubes. The samples were stored at 80C until they were shipped for analysis
in dry ice. Clinical and dietary information is available in Table S3.
Glycosaminoglycan Analysis
Sample preparation including extraction and purification steps were per-
formed as previously described by Coppa et al. (2011) and Volpi and Maccari
(2005a, 2005b), while sample GAGs separation and quantification were per-
formed as described in Volpi et al. (2014) and Volpi and Linhardt (2010).
Briefly, to extract the GAGs, 500 ml of sample was lyophilized, reconstituted
with 1 ml of a 20-mM TRIS-Cl buffer (pH 7.4), and treated with protease (pro-
teinase K from Tritirachium album [Enzyme Commisson 3.4.21.64], >500 U ml
from Sigma-Aldrich) at 60C for 12 hr. After boiling for 10 min, centrifugationand filtration was done on 0.45-mm filters, and the filtrate was lyophilized. The
powder was dissolved in 1 ml of distilled water by prolonged mixing. After
centrifugation at 5,000 3 g for 15 min, 0.2 ml of 20% trichloro-acetic acid
was added to the supernatant and stored for 2 hr at 4C. The mixture was
centrifuged at 5,000 3 g for 15 min, and the supernatant was recovered
and lyophilized for further purification on anion-exchange resin (QAE Sepha-
dex A-25). After reconstitution with 500 ml 10 mM NaCl and centrifugation at
10,000 3 g for 5 min, the supernatant was applied to a column (0.5 3 2 cm)
packed with about 0.4 ml of resin previously equilibrated with 10 mM NaCl.
After washing the resin with 2 ml of 10 mM NaCl, 1 ml of 2.5 M NaCl was
added. Fifty milliliters of ethanol was added to the eluate (1 ml) and stored
at 20C for 24 hr. After centrifugation at 5,000 3 g for 15 min, the pellet
was reconstituted in 160 ml of water and divided in two aliquots of 80 ml,
and both were lyophilized. One aliquot of the extracted GAGs was treated
with chondroitinase ABC, and the second one was submitted to heparinases
treatment. Unsaturated disaccharides generated by the treatment of ex-
tracted GAGs with enzymes were fluorotagged with 2-aminoacridone (Coppa
et al., 2011; Volpi and Maccari, 2005a, 2005b) and separated by capillary
electrophoresis equipped with laser induced fluorescence according to the
previous reported method (Volpi et al., 2014).
Eighteen independent GAG properties were measured in each sample
(either plasmatic or urinary): CS concentration, HS concentration, and frac-
tions of disaccharide composition for both CS and HS. The charge is the
sum over all sulfated disaccharide fractions. Principal component analysis
was performed on available GAG properties for three cases: only plasmatic,
only urinary, or both plasmatic and urinary (combined). Principal component
analysis was implemented using R-package ade4 (Dray and Dufour, 2007)
(centering was performed by the mean). All measurements are available in
Table S3.
Biomarker Design
To design the biomarkers in the only plasmatic or in the only urinary case, we
used Lasso penalized logistic regression (Tibshirani, 1996) with leave-one-out
cross-validation to select those GAG properties that are most predictive of the
clinical outcome (i.e., mccRCC versus healthy) at the optimal Lasso penalty
value. This was calculated using the glmnet R-package (Friedman et al.,
2010) as the penalty value for which the cross-validation error was within 1
SE of the minimum. The biomarkers were built as the ratio between the sum
of the GAG properties robustly predictive of mccRCC over the sum of the
GAG properties robustly predictive of healthy state. Each property value
was normalized using the respective regression coefficient (rounded to the
nearest rational number). The biomarker for the combined case was taken
as themean of the so-designed plasmatic and urinary biomarkers. The highest
density interval (HDI) for the mean difference in biomarker scores between
mccRCC versus healthy was calculated using Bayesian estimation under the
following assumptions: scores are sampled from a t-distribution of unknown
and to be estimated normality (i.e., degrees of freedom); high uncertainty on
the prior distributions; the marginal distribution is well approximated by a
Markov chain Monte Carlo sampling with no thinning and chain length equal
to 100,000. The estimation was performed using BEST (Kruschke, 2013)
(the above assumptions are reflected by the default parameters). Bayesian
estimation was preferred over the widely used t test since it provides a robust
and reliable estimation ofmean difference even under uncertainty of the under-
lying score distribution for the two groups (that is the case when the number of
samples is limited) (Nuzzo, 2014).
Accuracy Metrics
For each biomarker (plasma, urine, or combined), we evaluated its perfor-
mance in the binary classification of a sample as either mccRCC or healthy
at varying threshold scores by deriving the receiver operating characteristic
(ROC) curves. We measured the accuracy of each biomarker as the area un-
der the curve (AUC) of its ROC curve (AUC is 1 for a perfect classifier and 0.5
for a random classifier). We selected as a potential cutoff value for a given
biomarker the score for which the positive predictive value was maximum;
i.e., a sample whose biomarker score is above this cutoff value has the
maximum probability of being mccRCC. The ROC curves were calculated
using the pROC R-package (Robin et al., 2011), while the optimal cutoffCell Reports 15, 1822–1836, May 24, 2016 1833
was calculated using the OptimalCutpoints R-package (Lopez-Raton et al.,
2014).
Analysis of Covariance
The analysis of covariance was performed using logistic regression on the
clinical outcome (mccRCC versus control) on selected covariates among
those reported in the clinical and dietary information in Table S3. These co-
variates were selected using Lasso penalized logistic regression with leave-
one-out cross-validation as the most predictive of the clinical outcome at the
optimal Lasso penalty value (chosen as described in Biomarker design).
These covariates are age, weekly consumption of pasta and rice, and use
of alcohol. Next, we performed logistic regression on the clinical outcome
based on the combined score and the four selected covariates. The signifi-
cance of each coefficient was tested using the Wald z-statistics for the hy-
pothesis that the corresponding parameter is zero. The same procedure
was followed to check the effect of systemic therapy as covariate, but using
only plasma samples to regress the clinical outcome (since only for such
sub-cohort there were enough patients that did not undergo any systemic
therapy). In this case, either only one covariate was used to indicate the
presence or absence of undergoing therapy or a second covariate to ac-
count for the specific effect of sunitinib was added. Logistic regression
was implemented adopting the Firth bias-reduction method using the brglm
R-package. The performance of the two alternative models for logistic
regression (either combined score + age + weekly consumption of pasta +
weekly consumption of rice + use of alcohol; or combined score) was eval-
uated according to the minimum Kullback-Leibler divergence criterion by
calculating the Akaike’s information criterion (AIC) for the models and
deriving the model probability in terms of AIC weights (Wagenmakers and
Farrell, 2004).
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